Predictors of Competing Mortality in Advanced Head and Neck Cancer

被引:109
作者
Mell, Loren K. [1 ]
Dignam, James J.
Salama, Joseph K.
Cohen, Ezra E. W.
Polite, Blase N.
Dandekar, Virag
Bhate, Amit D.
Witt, Mary Ellyn
Haraf, Daniel J.
Mittal, Bharat B.
Vokes, Everett E.
Weichselbaum, Ralph R.
机构
[1] Univ Calif San Diego, Moores Canc Ctr, Dept Radiat Oncol, La Jolla, CA 92129 USA
关键词
SQUAMOUS-CELL CARCINOMA; LOCOREGIONALLY ADVANCED HEAD; LOCALLY ADVANCED HEAD; CONCURRENT CHEMOTHERAPY; SURVIVAL; CHEMORADIOTHERAPY; FLUOROURACIL; RADIOTHERAPY; THERAPY; IRRADIATION;
D O I
10.1200/JCO.2008.20.9288
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Death from noncancer causes (competing mortality) is an important event in head and neck cancer, but studies identifying predictors of this event are lacking. We sought to identify predictors of competing mortality and develop a risk stratification model for competing events. Patients and Methods Cohort study of 479 patients with stage III to IV carcinoma of the head and neck diagnosed between August 1993 and November 2004. Patients were treated on consecutive prospective clinical trials involving organ-preserving chemoradiotherapy and surgery. We used multivariable competing risks regression models to analyze factors associated with the cumulative incidence of competing mortality, locoregional and distant failure, and second malignancies as first events. Results Median follow-up was 52 months median for survivors. The 5-year cumulative incidence of competing mortality was 19.6% (95% CI, 15.8 to 23.4). On multivariable analysis, competing mortality was associated with female sex (hazard ratio [HR], 1.72; 95% CI, 1.13 to 2.63), increasing age (HR, 1.30; 95% CI, 1.04 to 1.62), increasing Charlson Comorbidity Index (HR, 1.24; 95% CI, 1.05 to 1.47), decreasing body mass index (HR, 0.33; 95% CI, 0.13 to 0.84), and decreasing distance traveled to the treating center (HR, 0.65; 95% CI, 0.44 to 0.98). Patients with zero, one, two, and >= three risk factors had 5-year competing mortality of 8.9% (95% CI, 3.0% to 14.8%), 12.4% (95% CI, 7.0% to 17.8%), 22.1% (95% CI, 14.5% to 29.7%), and 39.3% (95% CI, 28.6% to 50.1%), respectively. Conclusion Competing mortality in advanced head and neck cancer is associated with several demographic and health status characteristics. Analyses of risk factors for competing mortality may be useful in outcomes reporting and designing clinical trials.
引用
收藏
页码:15 / 20
页数:6
相关论文
共 32 条
[11]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[12]   Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer [J].
Forastiere, AA ;
Goepfert, H ;
Maor, M ;
Pajak, TF ;
Weber, R ;
Morrison, W ;
Glisson, B ;
Trotti, A ;
Ridge, JA ;
Chao, C ;
Peters, G ;
Lee, DJ ;
Leaf, A ;
Ensley, J ;
Cooper, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (22) :2091-2098
[13]   Composite outcomes in randomized trials - Greater precision but with greater uncertainty? [J].
Freemantle, N ;
Calvert, M ;
Wood, J ;
Eastaugh, J ;
Griffin, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19) :2554-2559
[14]   ON THE USE OF CAUSE-SPECIFIC FAILURE AND CONDITIONAL FAILURE PROBABILITIES - EXAMPLES FROM CLINICAL ONCOLOGY DATA [J].
GAYNOR, JJ ;
FEUER, EJ ;
TAN, CC ;
WU, DH ;
LITTLE, CR ;
STRAUS, DJ ;
CLARKSON, BD ;
BRENNAN, MF .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1993, 88 (422) :400-409
[15]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[16]  
Hanrahan EO, 2007, J CLIN ONCOL, V25, P4952, DOI 10.1200/JCO.2006.08.0499
[17]  
Haraf DJ, 2003, CLIN CANCER RES, V9, P5936
[18]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[19]   APPLICATIONS OF CRUDE INCIDENCE CURVES [J].
KORN, EL ;
DOREY, FJ .
STATISTICS IN MEDICINE, 1992, 11 (06) :813-829
[20]   Is patient travel distance associated with survival on phase II clinical trials in oncology? [J].
Lamont, EB ;
Hayreh, D ;
Pickett, KE ;
Dignam, JJ ;
List, MA ;
Stenson, KM ;
Haraf, DJ ;
Brockstein, BE ;
Sellergren, SA ;
Vokes, EE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1370-1375